These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

447 related items for PubMed ID: 17120686

  • 1. [The role of biological agents in the treatment of psoriatic arthritis, literature review].
    Koó E, Brodszky V, Péntek M, Ujfalussy I, Nagy MB, Gulácsi L.
    Orv Hetil; 2006 Oct 15; 147(41):1963-70. PubMed ID: 17120686
    [Abstract] [Full Text] [Related]

  • 2. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
    Barra L, Pope JE, Payne M.
    J Rheumatol; 2009 Jul 15; 36(7):1421-8. PubMed ID: 19487267
    [Abstract] [Full Text] [Related]

  • 3. Matching-adjusted indirect comparison of adalimumab vs etanercept and infliximab for the treatment of psoriatic arthritis.
    Kirson NY, Rao S, Birnbaum HG, Kantor E, Wei RS, Cifaldi M.
    J Med Econ; 2013 Jul 15; 16(4):479-89. PubMed ID: 23339434
    [Abstract] [Full Text] [Related]

  • 4. Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis.
    Girolomoni G, Altomare G, Ayala F, Berardesca E, Calzavara-Pinton P, Chimenti S, Peserico A, Puglisi Guerra A, Vena GA.
    Immunopharmacol Immunotoxicol; 2012 Aug 15; 34(4):548-60. PubMed ID: 22296031
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. [Treatment of psoriatic arthritis with TNF alpha-antagonists].
    Antoni C, Manger B.
    Z Rheumatol; 2003 Jun 15; 62(3):235-9. PubMed ID: 12827399
    [Abstract] [Full Text] [Related]

  • 7. Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study.
    Saougou I, Markatseli TE, Papagoras C, Voulgari PV, Alamanos Y, Drosos AA.
    Semin Arthritis Rheum; 2011 Apr 15; 40(5):398-406. PubMed ID: 20843542
    [Abstract] [Full Text] [Related]

  • 8. Update on anti-tumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritis.
    Kavanaugh A, Tutuncu Z, Catalan-Sanchez T.
    Curr Opin Rheumatol; 2006 Jul 15; 18(4):347-53. PubMed ID: 16763453
    [Abstract] [Full Text] [Related]

  • 9. Long-term work disability in patients with psoriatic arthritis treated with anti-tumour necrosis factor: a population-based regional Swedish cohort study.
    Kristensen LE, Englund M, Neovius M, Askling J, Jacobsson LT, Petersson IF.
    Ann Rheum Dis; 2013 Oct 15; 72(10):1675-9. PubMed ID: 23148309
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Anti-TNF alpha in the treatment of psoriatic arthritis].
    Claudepierre P, Wendling D, Cohen JD.
    Presse Med; 2006 Apr 15; 35(4 Pt 2):647-55. PubMed ID: 16614610
    [Abstract] [Full Text] [Related]

  • 14. Effectiveness of psoriatic arthritis therapies.
    Gladman DD.
    Semin Arthritis Rheum; 2003 Aug 15; 33(1):29-37. PubMed ID: 12920694
    [Abstract] [Full Text] [Related]

  • 15. [The role of biologic agents in the therapy of ankylosing spondylitis].
    Géher P, Nagy MB, Péntek M, Tóth E, Brodszky V, Gulácsi L.
    Orv Hetil; 2006 Jul 02; 147(26):1203-13. PubMed ID: 16898082
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis.
    Fénix-Caballero S, Alegre-del Rey EJ, Castaño-Lara R, Puigventós-Latorre F, Borrero-Rubio JM, López-Vallejo JF.
    J Clin Pharm Ther; 2013 Aug 02; 38(4):286-93. PubMed ID: 23590560
    [Abstract] [Full Text] [Related]

  • 19. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital.
    Wick MC, Ernestam S, Lindblad S, Bratt J, Klareskog L, van Vollenhoven RF.
    Scand J Rheumatol; 2005 Aug 02; 34(5):353-8. PubMed ID: 16234182
    [Abstract] [Full Text] [Related]

  • 20. Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period.
    Conti F, Ceccarelli F, Marocchi E, Magrini L, Spinelli FR, Spadaro A, Scrivo R, Valesini G.
    Ann Rheum Dis; 2007 Oct 02; 66(10):1393-7. PubMed ID: 17613555
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.